• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 7
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue7

A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19

    Dr.Elayakumar S.T Dr. Anbumalar M

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 5752-5757

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Although a viral infection begins in COVID-19, some patients have overly exuberant inflammation, leading to acute pulmonary injury and a condition of adult respiratory distress (ARDS). As IL-6 is a key role in the inflammatory response, in this single centre observatory study in all Covid-19 patients with a proven SARS-CoV-2 fast-pacing infection in order to escape ALI and ARDS we have assessed the effectiveness and protection of tocilizumab (TCZ). In this single centre The rate of mortality in 104 patients treated for COVID-19 was lower (5 · 8%). The percentage of patients treated with COVID-19 was 11% lower than in untreated patients who had our level of treatment alone and a marginally lower rate of mortality (6 percent ). The acute phase reagents, Ferritin, and liver protein releases were quickly diminished by TCZ. Slowly, D-Dimer declined. Relevant safety issues were not found. An early prescribing of IL6-R antagonists can be safe and successful for avoidance, ICU admission and more complications in COVID-19 patients with imminent hyperinflammatory reaction1.
Keywords:
    COVID_19 Tocilizumab Pandemic treatment
  • PDF (214 K)
  • XML
(2020). A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19. European Journal of Molecular & Clinical Medicine, 7(7), 5752-5757.
Dr.Elayakumar S.T; Dr. Anbumalar M. "A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19". European Journal of Molecular & Clinical Medicine, 7, 7, 2020, 5752-5757.
(2020). 'A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19', European Journal of Molecular & Clinical Medicine, 7(7), pp. 5752-5757.
A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19. European Journal of Molecular & Clinical Medicine, 2020; 7(7): 5752-5757.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 17
  • PDF Download: 10
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  info@ejmcm.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

Editorial Team:  editor@ejmcm.com

For Special Issue Proposal : chiefeditor.ejmcm@gmail.com / info@ejmcm.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus